Biontech Se Sponsored Adr (BNTX)
NASDAQ:BNTX
Want to see BNTX full AI Analyst Report?
BNTX Stock Chart & Stats
$102.92
-$4.73(-3.73%)
At close: 4:00 PM EST
$102.92
-$4.73(-3.73%)
Day’s Range― - ―
52-Week Range$79.52 - $124.00
Previous CloseN/A
Volume316.50K
Average Volume (3M)959.16K
Market Cap
$24.26B
Enterprise Value$11.13B
Total Cash (Recent Filing)$14.65B
Total Debt (Recent Filing)$303.12M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 04, 2026EPS Estimate
-2.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.09
Shares Outstanding252,884,260
10 Day Avg. Volume983,732
30 Day Avg. Volume959,165
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue3.98
Enterprise Value/Gross Profit5.43
Enterprise Value/Ebitda-13.65
Forecast
1Y Price Target
$131.39Price Target Upside27.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-4.58
Revenue Forecast (FY)$2.15B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity create durable financial optionality: BioNTech can fund multi-year, high-cost oncology development, absorb trial setbacks, and pursue strategic deals or manufacturing consolidation without immediate financing stress, supporting execution over the next 2–6 months and beyond.
Improving Free Cash FlowPositive free cash flow in 2025 and TTM signals the company can increasingly fund operations and late-stage trials internally. That reduces dilution risk and provides a steady funding base for commercialization investments and milestone-driven programs over the medium term, despite historic volatility.
Late-stage Oncology Pipeline BreadthA broad, late-stage oncology slate with thousands enrolled and multiple Phase 3 programs materially increases the probability of near- to medium-term new product approvals. Successful readouts would diversify revenue beyond COVID franchises and structurally transform BioNTech toward a sustainable multi-product commercial company.
Bears Say
2026 Revenue Decline GuidanceA guided material revenue drop reflects post-pandemic normalization and reduced COVID franchise contribution. That lowers near-term top-line cover for rising R&D and SG&A, forcing reliance on pipeline catalysts and cash reserves to bridge the commercialization gap over the next 2–6 months.
Deteriorated Profitability ProfileHigh gross margins insulated by COVID-era product mix are now offset by elevated operating spend. Until new oncology revenues ramp, persistent negative operating and net margins will pressure returns and could limit reinvestment flexibility, making near-term profitability recovery uncertain.
Founders' Transition And Execution RiskA planned leadership and scientific transition during a catalyst-rich period raises execution risk: loss of founding scientific leaders could affect strategic continuity, partner relationships and trial prioritization. Operational handover complexity may strain commercialization readiness in the medium term.
BioNTech SE News
BNTX FAQ
What was Biontech Se Sponsored Adr’s price range in the past 12 months?
Biontech Se Sponsored Adr lowest stock price was $79.52 and its highest was $124.00 in the past 12 months.
What is Biontech Se Sponsored Adr’s market cap?
Biontech Se Sponsored Adr’s market cap is $24.26B.
When is Biontech Se Sponsored Adr’s upcoming earnings report date?
Biontech Se Sponsored Adr’s upcoming earnings report date is Aug 04, 2026 which is in 63 days.
How were Biontech Se Sponsored Adr’s earnings last quarter?
Biontech Se Sponsored Adr released its earnings results on May 05, 2026. The company reported -$2.446 earnings per share for the quarter, beating the consensus estimate of -$2.559 by $0.113.
Is Biontech Se Sponsored Adr overvalued?
According to Wall Street analysts Biontech Se Sponsored Adr’s price is currently Undervalued.
Does Biontech Se Sponsored Adr pay dividends?
Biontech Se Sponsored Adr pays a Notavailable dividend of $2.111 which represents an annual dividend yield of N/A. See more information on Biontech Se Sponsored Adr dividends here
What is Biontech Se Sponsored Adr’s EPS estimate?
Biontech Se Sponsored Adr’s EPS estimate is -2.45.
How many shares outstanding does Biontech Se Sponsored Adr have?
Biontech Se Sponsored Adr has 252,884,260 shares outstanding.
What happened to Biontech Se Sponsored Adr’s price movement after its last earnings report?
Biontech Se Sponsored Adr reported an EPS of -$2.446 in its last earnings report, beating expectations of -$2.559. Following the earnings report the stock price went down -3.875%.
Which hedge fund is a major shareholder of Biontech Se Sponsored Adr?
Currently, no hedge funds are holding shares in BNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$131.39 (27.66% Upside)
$131.39 (27.66% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 102.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Bullish
Bullish news 79%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.28%
12-Months-Change
Fundamentals
Return on Equity
-6.67%
Trailing 12-Months
Asset Growth
6.12%
Trailing 12-Months
Company Description
Biontech Se Sponsored Adr
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Company Deck
BNTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented a constructive picture: BioNTech outperformed its raised 2025 guidance, preserved a very strong cash position (EUR 17.2 billion), advanced a broad late-stage oncology pipeline with multiple planned readouts in 2026–2030, and executed strategic deals to derisk programs. Offsetting this, management guided materially lower revenues for 2026 (EUR 2.0–2.3bn vs EUR 2.9bn in 2025), highlighted near-term increases in R&D and SG&A to support oncology launches, reported an adjusted net loss (EUR 117m) and disclosed a trial discontinuation in one indication. The founders' planned transition to a new company introduces execution uncertainty but is framed as an orderly process through end-2026. On balance, the positive operational progress, portfolio de-risking and very strong liquidity outweigh the near-term revenue headwinds and costs.View all BNTX earnings summariesBNTX Stock 12 Month Forecast
Average Price Target
$131.39
▲(27.66% Upside)
Technical Analysis
Ownership Overview
0.50% Insiders
7.15% Mutual Funds
10.24% Other Institutional Investors
80.94% Public Companies and Individual Investors